Abstract
Current evidence suggests a central role for antithrombotic agents such as unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH) in the management of acute coronary syndromes (ACS). In patients with acute myocardial infarction, several studies have shown that LMWHs may represent an effective alternative to UFH as an adjunct to thrombolytic therapy and are not associated with an increased risk of major bleeding. In patients with unstable angina or non-ST-segment elevation myocardial infarction, trials have shown that the LMWH enoxaparin significantly reduces the risk of cardiovascular events, compared with UFH, while other trials have shown that the combination of enoxaparin and a glycoprotein IIb/IIIa antagonist is not associated with an excess risk of bleeding. However, LMWHs are significantly more expensive that UFH. Recently, newer antithrombotic agents such as fondaparinux and bivalirudin have shown equivalent efficacy to the heparins with less bleeding and appear clinically attractive. This review examines the current evidence for the efficacy and safety of antithrombotic agents in ACS.
Keywords: Heparin, acute coronary syndromes, low-molecular-weight heparin
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title: Antithrombotic Agents for Acute Coronary Syndromes
Volume: 6 Issue: 2
Author(s): Debabrata Mukherjee
Affiliation:
Keywords: Heparin, acute coronary syndromes, low-molecular-weight heparin
Abstract: Current evidence suggests a central role for antithrombotic agents such as unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH) in the management of acute coronary syndromes (ACS). In patients with acute myocardial infarction, several studies have shown that LMWHs may represent an effective alternative to UFH as an adjunct to thrombolytic therapy and are not associated with an increased risk of major bleeding. In patients with unstable angina or non-ST-segment elevation myocardial infarction, trials have shown that the LMWH enoxaparin significantly reduces the risk of cardiovascular events, compared with UFH, while other trials have shown that the combination of enoxaparin and a glycoprotein IIb/IIIa antagonist is not associated with an excess risk of bleeding. However, LMWHs are significantly more expensive that UFH. Recently, newer antithrombotic agents such as fondaparinux and bivalirudin have shown equivalent efficacy to the heparins with less bleeding and appear clinically attractive. This review examines the current evidence for the efficacy and safety of antithrombotic agents in ACS.
Export Options
About this article
Cite this article as:
Mukherjee Debabrata, Antithrombotic Agents for Acute Coronary Syndromes, Cardiovascular & Hematological Agents in Medicinal Chemistry 2008; 6 (2) . https://dx.doi.org/10.2174/187152508783955042
DOI https://dx.doi.org/10.2174/187152508783955042 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Carotid Artery Disease: Current Concepts on Endothelial Dysfunction and Matrix Remodeling
Current Drug Therapy Targeting the Toll-System in Cardiovascular Sciences
Recent Patents on Inflammation & Allergy Drug Discovery Inflammatory Syndrome in Chronic Kidney Disease: Pathogenesis and Influence on Outcomes
Inflammation & Allergy - Drug Targets (Discontinued) Cholesteryl Ester Transfer Protein: Pharmacological Inhibition for the Modulation of Plasma Cholesterol Levels and Promising Target for the Prevention of Atherosclerosis.
Current Topics in Medicinal Chemistry Hematopoietic Progenitor and Stem Cells Circulate by Surfing on Intracellular Ca2+ Waves: A Novel Target for Cell-based Therapy and Anti-cancer Treatment?
Current Signal Transduction Therapy Recent Advances and Patents on Coronary Sinus Perfusion Devices for Treatment of Heart Disease
Recent Patents on Biomedical Engineering (Discontinued) The Double Roles of the Prostaglandin E<sub>2</sub> EP2 Receptor in Intracerebral Hemorrhage
Current Drug Targets The Role of Adipocytokines in Atherogenesis and Atheroprogression
Current Drug Targets Statin Therapy-Evidence Beyond Lipid Lowering Contributing to Plaque Stability
Current Medicinal Chemistry Canonical and Non-Canonical Barriers Facing AntimiR Cancer Therapeutics
Current Medicinal Chemistry The Effects of Newer Beta-Adrenoceptor Antagonists on Vascular Function in Cardiovascular Disease
Current Vascular Pharmacology Endothelial Remodelling and Intracellular Calcium Machinery
Current Molecular Medicine The Multiple Layers of Signaling Selectivity at Protease-Activated Receptors
Current Pharmaceutical Design Angiogenesis, Neurogenesis and Neuroplasticity in Ischemic Stroke
Current Cardiology Reviews On the Involvement of Mitochondrial Intermembrane Junctional Complexes in Apoptosis
Current Medicinal Chemistry Immunobiology of Antigen-Specific Immunoglobulin Free Light Chains in Chronic Inflammatory Diseases
Current Pharmaceutical Design Endoscopic Microscopy Using Optical Coherence Tomography
Current Medical Imaging Nanotechnology for Delivery of Drugs and Biomedical Applications
Current Clinical Pharmacology Contrast-enhanced Ultrasound for Liver Imaging: Recent Advances
Current Pharmaceutical Design Regulation of Myocardial Extracellular Matrix Dynamic Changes in Myocardial Infarction and Postinfarct Remodeling
Current Cardiology Reviews